Edward J. Dulac III
Chief Accounting Officer
Fate Therapeutics Inc (FATE)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Edward J. Dulac III
Edward J. Dulac III is recorded as Chief Accounting Officer at Fate Therapeutics Inc (FATE). Fate Therapeutics Inc reported in an 8-K filed June 7, 2024 that Edward J. Dulac III resigned as Chief Financial Officer, effective June 14, 2024. Fate Therapeutics Inc reported in an 8-K filed May 31, 2024 that Edward J. Dulac III resigned as Chief Financial Officer, effective June 14, 2024. The proxy statement of Fate Therapeutics Inc reports total compensation of $2,824,498 for Edward J. Dulac III in fiscal 2023, including a base salary of $475,000. Disclosed compensation is on record for 4 fiscal years.
“Mr. Dulac provided notice of his resignation from his position as the Company’s Chief Financial Officer on May 30, 2024, which resignation shall be effective as of June 14, 2024.”
“On May 30, 2024, Edward J. Dulac III provided notice of his resignation from his position as Chief Financial Officer of Fate Therapeutics, Inc. (the "Company"), which will be effective June 14, 2024.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2020-08-17–present
-
Start not stated–2024-06-14
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Fate Therapeutics Inc
Other people whose current roles at this company are on record from its filings.
- Bahram Valamehr CEO, Board Member
- Scott Wolchko CEO, Board Member
- William H. Rastetter Chairman
- J. Scott Wolchko CFO, Chief Accounting Officer
- Kamal Adawi CFO, Chief Accounting Officer
- Cindy R. Tahl General Counsel
- Karin Jooss Board Member
- Karin Jooss, Ph.D. Board Member
- Laura J. Hamill Board Member
- Matthew Abernethy Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Fate Therapeutics Inc (FATE) | Chief Financial Officer | $475,000 | $2,824,498 |
| 2022 | Fate Therapeutics Inc (FATE) | Chief Financial Officer | $455,000 | $3,157,751 |
| 2021 | Fate Therapeutics Inc (FATE) | Chief Financial Officer | $420,000 | $6,384,051 |
| 2020 | Fate Therapeutics Inc (FATE) | Chief Financial Officer | $142,500 | $5,683,579 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.